Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older
• People who have been diagnosed with a type of blood disorder called a myeloproliferative neoplasm (MPN) — which may include polycythemia vera, essential thrombocythemia, primary or secondary myelofibrosis, or related conditions — and whose disease has now progressed to show at least 5% abnormal (blast) cells in the bone marrow or blood, confirmed by a pathologist
• People whose previous diagnostic test results (such as bone marrow or blood slides) from another facility are acceptable, as long as those samples are also reviewed by pathology at the study site
• People who are reasonably active and able to care for themselves, as measured by standard medical scoring tools (confirm with trial site)
• People whose kidneys are functioning at an adequate level, based on a blood test taken within 14 days of starting the trial
• People whose liver function results are within acceptable ranges, based on blood tests taken within 14 days of starting the trial (some exceptions may apply if liver results are affected by the underlying condition)
• People receiving a specific study drug called fedratinib who have adequate levels of a vitamin called thiamine in their blood — or whose thiamine levels have been brought back to normal before starting treatment
• People whom their treating doctor considers a potential candidate for a stem cell transplant
• People who have previously taken a medication called hydroxyurea, or who have received limited emergency treatment to control very high white blood cell counts before enrolling
• People who are able to understand the study and provide their own informed consent

Who may not be able to join:

• People who have already received chemotherapy treatments (such as hypomethylating agents or cytarabine-based regimens) specifically for MPN with 5% or more blast cells — though prior use of hydroxyurea, interferons, or JAK inhibitor therapy is permitted
• People with an active, uncontrolled infection caused by a fungus, bacteria, virus, or other organism (people with infections that are being treated and are stable may still be considered)
• People with a known allergic reaction to any of the study drugs
• People who are pregnant or breastfeeding
• People who have taken another investigational (experimental) drug for a related blood disorder within 2 weeks of starting this trial
• People planned to receive the study drug fedratinib who are taking certain other medications that strongly affect how the body processes drugs (specifically strong or moderate CYP3A4 inducers, or dual CYP3A4 and CYP2C19 inhibitors) and who are unable to stop those medications (confirm specific medications with trial site)
• People planned to receive the study drug ruxolitinib who have a low platelet count (below 50,000/mm²) and are taking a strong CYP3A4 inhibitor that cannot be stopped (confirm specific medications with trial site)
• People planned to receive the study drug pacritinib who have an abnormal heart rhythm reading (a QTc interval greater than 480 milliseconds) that cannot be corrected by adjusting medications or electrolyte levels
• People planned to receive pacritinib who are taking certain other medications that interact with how pacritinib is processed in the body and who cannot stop those medications (confirm specific medications with trial site)

Important: Always verify eligibility with the trial site directly before applying.